Forms and compositions of an ERK inhibitor
The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of one or both of ERK1 and ERK2.
1. Compound 2:
2. The compound according to claim 1 , wherein said compound is crystalline.
3. The compound according to claim 1 , wherein said compound is a crystalline solid substantially free of amorphous compound 2.
4. The compound according to claim 2 , having one or more peaks in its XRPD selected from those at about 6.8, about 10.1, and about 20.8 degrees 2-theta.
5. The compound according to claim 4 , having at least two peaks in its XRPD selected from those at about 6.8, about 10.1, and about 20.8 degrees 2-theta.
6. The compound according to claim 5 , wherein said compound is of Form A.
7. The compound according to claim 2 , having an XRPD substantially similar to that depicted in FIG. 13 .
8. The compound according to claim 2 , having one or more peaks in its XRPD selected from those at about 3.6, about 7.3, and about 15.0 degrees 2-theta.
9. The compound according to claim 8 , having at least two peaks in its XRPD selected from those at about 3.6, about 7.3, and about 15.0 degrees 2-theta.
10. The compound according to claim 9 , wherein said compound is of Form B.
11. The compound according to claim 2 , having an XRPD substantially similar to that depicted in FIG. 17 .
12. The compound according to claim 2 , having one or more peaks in its XRPD selected from those at about 8.4, about 9.3, and about 16.5 degrees 2-theta.
13. The compound according to claim 12 , having at least two peaks in its XRPD selected from those at about 8.4, about 9.3, and about 16.5 degrees 2-theta.
14. The compound according to claim 13 , wherein said compound is of Form C.
15. The compound according to claim 2 , having an XRPD substantially similar to that depicted in FIG. 21 .
16. The compound according to claim 2 , having one or more peaks in its XRPD selected from those at about 9.1, about 10.4, and about 25.1 degrees 2-theta.
17. The compound according to claim 16 , having at least two peaks in its XRPD selected from those at about 9.1, about 10.4, and about 25.1 degrees 2-theta.
18. The compound according to claim 17 , wherein said compound is of Form D.
19. The compound according to claim 2 , having an XRPD substantially similar to that depicted in FIG. 25 .
20. A pharmaceutical composition comprising the compound according to claim 1 and a pharmaceutically acceptable carrier or excipient.
21. The pharmaceutical composition according to claim 20 , wherein said pharmaceutical composition is substantially free of impurities.